Durata Therapeutics Company Profile (NASDAQ:DRTX)

About Durata Therapeutics

Durata Therapeutics logoDurata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: DRTX
  • CUSIP: 26658A10
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $0
  • 200 Day Moving Average: $24
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -17.64
  • P/E Growth: 0
  • Market Cap: $N/A
Additional Links:
Companies Related to Durata Therapeutics:

Analyst Ratings

Consensus Ratings for Durata Therapeutics (NASDAQ:DRTX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Durata Therapeutics (NASDAQ:DRTX)
Show:
DateFirmActionRatingPrice TargetDetails
10/15/2014Roth CapitalDowngradeBuy -> Neutral$23.00View Rating Details
10/14/2014Credit Suisse Group AGDowngradeOutperform -> Neutral$25.00View Rating Details
10/7/2014Royal Bank Of CanadaDowngradeOutperform -> Sector PerformView Rating Details
10/6/2014JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
(Data available from 8/28/2014 forward)

Earnings

Earnings History for Durata Therapeutics (NASDAQ:DRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2014Q2($0.73)($0.61)ViewN/AView Earnings Details
5/8/2014Q114($0.64)($0.62)ViewN/AView Earnings Details
3/14/2014Q413($0.76)($0.59)ViewN/AView Earnings Details
11/6/2013($0.60)($0.45)ViewN/AView Earnings Details
8/7/2013Q2 2013($0.52)($0.75)ViewN/AView Earnings Details
5/9/20131Q13($0.66)($0.86)ViewN/AView Earnings Details
11/9/2012Q312($1.00)($1.47)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Durata Therapeutics (NASDAQ:DRTX)
Current Year EPS Consensus Estimate: $-2.97 EPS
Next Year EPS Consensus Estimate: $-1.37 EPS

Dividends

Dividend History for Durata Therapeutics (NASDAQ:DRTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Durata Therapeutics (NASDAQ:DRTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/12/2014John Patrick Shannon JrInsiderBuy3,000$13.72$41,160.00View SEC Filing  
6/12/2014Paul R EdickCEOBuy3,000$15.23$45,690.00View SEC Filing  
5/12/2014Schutter Richard DeDirectorBuy15,000$15.57$233,550.00View SEC Filing  
3/21/2014Aisling Capital Iii Lpmajor shareholderSell100,649$15.74$1,584,215.26View SEC Filing  
12/3/2013Lisa GilesDirectorBuy1,000$10.95$10,950.00View SEC Filing  
5/20/2013Paul R EdickCEOBuy3,000$7.09$21,270.00View SEC Filing  
8/14/2012Paul R EdickCEOBuy5,000$8.65$43,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Durata Therapeutics (NASDAQ:DRTX)
DateHeadline
noodls.com logoActavis Launches U.S. Generic Specialty Injectable Portfolio (NASDAQ:DRTX)
www.noodls.com - January 20 at 3:30 AM
sg.finance.yahoo.com logoActavis buying Durata Therapeutics for $616.4 (NASDAQ:DRTX)
sg.finance.yahoo.com - October 6 at 8:34 AM

Social

Durata Therapeutics (NASDAQ:DRTX) Chart for Sunday, August, 28, 2016


Last Updated on 8/28/2016 by MarketBeat.com Staff